Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, Morinaga R, Terashima M, Miyazaki M, Okamoto I, Nishida Y, Tominaga S, Tokunaga Y, Yamaguchi M, Sakamoto J, Nakayama T, Nakagawa K.
Hayashi H, et al. Among authors: nakagawa k.
Breast Cancer. 2013 Apr;20(2):131-6. doi: 10.1007/s12282-011-0316-z. Epub 2011 Nov 29.
Breast Cancer. 2013.
PMID: 22124996
Clinical Trial.